Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
作者： Timothy J. Whelan , Paul E. Goss , James N. Ingle , Joseph L. Pater , Dongsheng Tu
关键词:
摘要: Purpose To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality life (QOL) in MA.17 trial. Methods Patients completed Short Form 36-item Health Survey (SF-36) and Menopause Specific Quality Life Questionnaire (MENQOL) at baseline, 6 months, annually. Mean change scores from baseline were between groups for summary measures domains. A response analysis proportion patients who demonstrated an important QOL.
elsevier.com
jco.org参考文章(19)
John E. Ware, SF-36 health survey: Manual and interpretation guide ,(2003)
Henning Mouridsen, Mikhail Gershanovich, Yan Sun, Ramón Pérez-Carrión, Corrado Boni, Alain Monnier, Justus Apffelstaedt, Robert Smith, Harm P. Sleeboom, Fritz Jänicke, Anna Pluzanska, Magdolna Dank, Dominique Becquart, Poonamalle P. Bapsy, Eeva Salminen, Ray Snyder, Mercedes Lassus, J. Arnold Verbeek, Beatrix Staffler, Hilary A. Chaudri-Ross, Margaret Dugan, Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group Journal of Clinical Oncology. ,vol. 19, pp. 2596- 2606 ,(2001) , 10.1200/JCO.2001.19.10.2596
J.M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, M. von Euler, Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial Journal of Clinical Oncology. ,vol. 18, pp. 3758- 3767 ,(2000) , 10.1200/JCO.2000.18.22.3758
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, H A Chaudri, U Hornberger, P F Trunet, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. ,vol. 16, pp. 453- 461 ,(1998) , 10.1200/JCO.1998.16.2.453
Gordon H Guyatt, David Osoba, Albert W Wu, Kathleen W Wyrwich, Geoffrey R Norman, Clinical Significance Consensus Meeting Group, Methods to explain the clinical significance of health status measures. Symposium on Quality of Life in Cancer Patients. ,vol. 77, pp. 371- 383 ,(2002) , 10.4065/77.4.371
Geoffrey R. Norman, Jeff A. Sloan, Kathleen W. Wyrwich, Interpretation of changes in health-related quality of life the remarkable universality of half a standard deviation Medical Care. ,vol. 41, pp. 582- 592 ,(2003) , 10.1097/01.MLR.0000062554.74615.4C
Mark A. Hlatky, Derek Boothroyd, Eric Vittinghoff, Penny Sharp, Mary A. Whooley, for the HERS Research Group, Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy JAMA. ,vol. 287, pp. 591- 597 ,(2002) , 10.1001/JAMA.287.5.591
Kathleen W. Wyrwich, Stephan D. Fihn, William M. Tierney, Kurt Kroenke, Ajit N. Babu, Fredric D. Wolinsky, Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. Journal of General Internal Medicine. ,vol. 18, pp. 196- 202 ,(2003) , 10.1046/J.1525-1497.2003.20203.X
David Osoba, Andrea Bezjak, Michael Brundage, Benny Zee, Dongsheng Tu, Joseph Pater, Quality of Life Committee of the NCIC CTG, Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group European Journal of Cancer. ,vol. 41, pp. 280- 287 ,(2005) , 10.1016/J.EJCA.2004.10.017